在小儿心脏外科手术后,阿尔金宁-瓦索普林的内分泌作用
Ilias Iliopoulos1, Saul Flores2, Matthew Coghill3
1Cardiac Intensive Care, Heart Center, INOVA Children's Hospital, 3300 Gallows Road, Falls Church, VA, USA. ilias.iliopoulos@inova.org.
Pediatric cardiology
|October 1, 2025
概括
在先天性心脏手术后的儿童中,氨酸-血管压素 (AVP) 治疗没有显著改变上腺皮质激素 (ACTH) 或皮质醇水平. AVP的血液动力学益处可能不是由于下丘脑-垂体-上腺轴.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 心血管外科心血管外科
- 关键护理医学 关键护理医学
背景情况:
- 众所周知,氨酸-血管压素 (AVP) 刺激上腺皮质激素 (ACTH) 分泌,并且可能在手术应激反应中发挥作用.
- 在患有先天性心脏手术的儿科患者中,AVP对内分泌的具体影响尚不清楚.
- 了解这些影响对于优化术后管理和患者的治疗结果至关重要.
研究的目的:
- 为了前性地评估氨酸-血管压素 (AVP) 治疗对先天性心脏手术后儿童上腺皮质激素 (ACTH) 和皮质醇水平的内分泌作用.
- 为了确定AVP的管理是否影响这个儿科群体的下丘脑-垂体-上腺 (HPA) 轴.
- 探索AVP水平,激素度和血液动力学参数之间的关联.
主要方法:
- 一项前性队列研究,涉及49名儿童 (平均年龄为8个月) 经过心肺旁路术的正心脏手术后.
- 患者被分为两组:接受AVP术后 (n=23) 和未接受治疗 (n=26) 的患者.
- 分析了皮质醇,ACTH,和葡萄糖的连续测量,以及基线激素水平 (AVP,ACTH,皮质醇,皮质醇结合型球蛋白) 和时间序列线性回归模型.
主要成果:
- 在AVP治疗和未治疗组之间,随着时间的推移,没有观察到ACTH或皮质醇水平的显著差异.
- 在接受AVP治疗的患者中观察到更高皮质醇水平的趋势,尽管这在统计学上并不显著.
- 回归分析显示,ACTH和皮质醇,皮质醇和缩血压,以及基线AVP水平与缩血压和脏氧气提取比率之间存在显著的关联.
结论:
- 在先天性心脏手术后的儿童中,氨酸-血管压素 (AVP) 治疗没有显著改变ACTH或皮质醇水平.
- 皮质醇和基线AVP水平在这个队列中独立与血液动力学标志物相关.
- 在儿科心脏外科手术中,AVP的血液动力学益处不太可能通过激活下丘脑-垂体-上腺轴来调节,因此需要在更大规模的研究中进一步调查.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Cardiomyopathy VII: Pre and Post Operative Nursing Management
287
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
287
Hormonal Regulation of Blood Pressure
5.9K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
5.9K
Heart Failure II: Pathophysiology
730
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.5K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.5K
Aortic Regurgitation III: Medical Management
397
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
397


